^
    Evidence Level:
    Resistant: B - Late Trials

    [TP53 mutation-Chronic Lymphocytic Leukemia-ofatumumab]

    Source:
    Haematologica
    Test:

    TruSeq®Amplicon - Cancer Panel

    Title:
    Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
    Published date:
    01/09/2020
    Excerpt:
    The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL...Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL))…Analyses of both treatment arms separately generally reiterated the results obtained for the total cohort, with mutations in SF3B1 and TP53 being associated with shorter PFS.
    Secondary therapy:
    chlorambucil
    DOI:
    10.3324/haematol.2019.229161
    Trial ID:
    COMPLEMENT 1
    Evidence Level:
    Resistant: B - Late Trials

    [TP53 mutation-Chronic Lymphocytic Leukemia-chlorambucil]

    Source:
    Haematologica
    Test:

    TruSeq®Amplicon - Cancer Panel

    Title:
    Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
    Published date:
    01/09/2020
    Excerpt:
    The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL))….Analyses of both treatment arms separately generally reiterated the results obtained for the total cohort, with mutations in SF3B1 and TP53 being associated with shorter PFS.
    DOI:
    10.3324/haematol.2019.229161
    Trial ID:
    COMPLEMENT 1
    Evidence Level:
    Resistant: B - Late Trials

    [SF3B1 mutation-Chronic Lymphocytic Leukemia-ofatumumab]

    Source:
    Haematologica
    Test:

    TruSeq®Amplicon - Cancer Panel

    Title:
    Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
    Published date:
    01/09/2020
    Excerpt:
    The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL))….Analyses of both treatment arms separately generally reiterated the results obtained for the total cohort, with mutations in SF3B1 and TP53 being associated with shorter PFS.
    Secondary therapy:
    chlorambucil
    DOI:
    10.3324/haematol.2019.229161
    Trial ID:
    COMPLEMENT 1
    Evidence Level:
    Resistant: B - Late Trials

    [SF3B1 mutation-Chronic Lymphocytic Leukemia-chlorambucil]

    Source:
    Haematologica
    Test:

    TruSeq®Amplicon - Cancer Panel

    Title:
    Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
    Published date:
    01/09/2020
    Excerpt:
    The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL))….Analyses of both treatment arms separately generally reiterated the results obtained for the total cohort, with mutations in SF3B1 and TP53 being associated with shorter PFS.
    DOI:
    10.3324/haematol.2019.229161
    Trial ID:
    COMPLEMENT 1
    Evidence Level:
    Resistant: B - Late Trials

    [NOTCH1 mutation-Chronic Lymphocytic Leukemia-ofatumumab]

    Source:
    Haematologica
    Test:

    TruSeq®Amplicon - Cancer Panel

    Title:
    Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
    Published date:
    01/09/2020
    Excerpt:
    The aim of this study was to evaluate the prognostic value of recurrent molecular abnormalities in patients with CLL. Therefore, we assessed their incidences and associations with other clinical and genetic markers in the prospective multicenter COMPLEMENT1 trial (treatment naive patients not eligible for intensive treatment randomized to chlorambucil (CHL) vs. ofatumumab-CHL (O-CHL))….for NOTCH1, we observed an impact on PFS in the O-CHL treatment arm (HR 1.94, 95%CI: 1.25-3.92, P<0.01) but not with CHL alone (HR 1.01, 95%CI: 0.69-1.47, P=0.98)...NOTCH1 as a predictive factor for reduced ofatumumab efficacy in a randomized chemo (immune)therapy CLL trial.
    Secondary therapy:
    chlorambucil
    DOI:
    10.3324/haematol.2019.229161
    Trial ID:
    COMPLEMENT 1